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Impact Statement: The manuscript demonstrates VASP Ser239 phosphorylation 
opposes malignant cell shape promoting invasion in colon cancer cells.  Induction of 
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VASP Ser239 phosphorylation may represent an innovative intervention to prevent tumor 
progression and metastasis in patients with colorectal cancer. 
 2
ABSTRACT 
In colorectal cancer, the antitumorigenic guanylyl cyclase C (GCC) signalome is 
defective reflecting ligand deprivation from downregulation of endogenous hormone 
expression.  Although the proximal intracellular mediators of that signal transduction 
system, including cyclic guanosine monophosphate (cGMP) and cGMP-dependent 
protein kinase (PKG), are well characterized, the functional significance of its distal 
effectors remain vague.  Dysregulation of ligand-dependent GCC signaling through 
vasodilator-stimulated phosphoprotein (VASP), an actin-binding protein implicated in 
membrane protrusion dynamics, drastically reduced cGMP-dependent VASP 
phosphorylation levels in colorectal tumors from patients.  Restoration of cGMP-
dependent VASP phosphorylation by GCC agonists suppressed the number and length of 
locomotory (filopodia) and invasive (invadopodia) actin-based organelles in human colon 
cancer cells.  Membrane organelle disassembly reflected specific phosphorylation of 
VASP Ser239, the cGMP/PKG preferred site, and rapid VASP removal from tumor cell 
protrusions.  Importantly, VASP Ser239 phosphorylation inhibited the proteolytic 
function of invadopodia, reflected by suppression of the cancer cell ability to digest DQ-
collagen IV embedded in Matrigel.  These results demonstrate a previously unrecognized 
role for VASP Ser239 phosphorylation, a single intracellular biochemical reaction, as an 
effective mechanism which opposes tumor cell shape promoting colon cancer invasion 
and metastasis.  Reconstitution of physiological cGMP circuitry through VASP, in turn, 
represents an attractive targeted approach for patients with colorectal cancer. 
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INTRODUCTION 
Despite considerable advancements in elucidating pathognomonic genetic and molecular 
alterations, the causal mechanisms underlying initiation and progression of colorectal 
cancer, the third most common and deadly neoplasm in the western world, remain 
unknown.  In the paracrine hormone hypothesis of colon cancer,1 tumorigenesis is 
characterized by a state of guanylyl cyclase C (GCC) ligand insufficiency, in which 
expression of endogenous hormones guanylin and uroguanylin, secreted by and 
activating GCC receptors on intestinal epithelial cells in an autocrine and paracrine 
fashion, is dramatically reduced following a yet unidentified event early during 
transformation.2-3  Ligand-induced GCC activation physiologically regulates intestinal 
fluid and electrolyte homeostasis through intracellular accumulation of the second 
messenger cyclic guanosine monophosphate (cGMP) and cGMP-dependent protein 
kinase (PKG) phosphorylation of ion channels.4  Activation of GCC also promotes the 
transition from the proliferative crypt phenotype to the differentiated colonocyte along 
intestinal mucosal surfaces by imposing cytostasis5 and oxidative metabolic 
reprogramming,6 effects presumably underlying GCC-mediated colorectal 
antitumorigenesis.7  Thus, the GCC ligandopenia associated with neoplastic 
transformation may promote colorectal carcinogenesis by producing a repressed GCC 
and cGMP pathway devoid of tumor suppressor activities.  However, the exact 
consequences at the molecular level of the absence of GCC activation in colon cancer 
cells are unclear. 
A poorly investigated target for the antitumorigenic GCC pathway is the vasodilator-
stimulated phosphoprotein (VASP).8  A mammalian member of the highly conserved 
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Ena/VASP family proteins, VASP acts as a molecular scaffold to bring together growing 
actin filaments with regulatory proteins at the cell leading edge.9  VASP controls cell 
spreading and migration by regulating the formation and stability of protrusive membrane 
structures driven by actin polymerization, including lamellipodia and filopodia, and the 
integrity of cell-matrix interactions at adhesion complexes.9  In that context, VASP exerts 
a pivotal role in filopodial dynamics, reflected by its localization at the filopodial tip 
complex where it promotes filopodia formation and elongation by recruiting the initial 
nanomachinery and imposing anti-capping pressure on actin filament barbed ends.10  
Three critical domains mediates VASP/actin interactions:9 1) the Ena/VASP homology 1 
(EVH1) domain at the N-terminus, which binds to proteins with poly-proline II helix, 
including vinculin and zyxin; 2) the central prolin-rich region, which binds to proteins 
containing SH3 and WW domains and the globular (G)-actin binding profilin, and 3) the 
EVH2 domain at the C-terminus, which binds to both G- and filamentous (F)-actin and 
mediates VASP oligomerization, thereby promoting F-actin bundling and stabilization.  
Importantly, VASP harbors 3 phosphorylation sites (Ser157, Ser239 and Thr278) which 
are targeted with different affinities by PKG, cAMP-dependent protein kinase and AMP-
activated protein kinase, and modulate its localization and function.11-13  Phosphorylation 
of VASP Ser239, adjacent to the G-actin binding site in the EVH2 domain, is selectively 
regulated by cGMP-dependent signaling through PKG,11 an event that disrupts VASP 
anti-capping and filament-bundling activities and inhibits membrane protrusion 
formation.9, 14 
While its engagement in migration and membrane protrusion dynamics in normal cells is 
well-established, a similar role for VASP Ser phosphorylation in cancer cells has not 
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emerged.  However, actin cytoskeletal remodeling at dynamic membrane regions 
determines oncogenic behaviors, from epithelial-to-mesenchymal transition to tissue 
invasion and metastasis.15-16  In principle, PKG-mediated VASP phosphorylation could 
represent one of the biochemical reactions of the antitumorigenic GCC/cGMP 
signalome.1  Here, human colon tumors exhibited reduced GCC ligand expression 
associated with depletion of cGMP-dependent VASP phosphorylation, indicating 
interruption of downstream signaling by the dysregulated GCC pathway.  Restoration of 
cGMP-mediated phosphorylation of VASP Ser239 by ligand-induced GCC signaling 
suppressed the invasive cancer cell phenotype, with disassembly of protrusive membrane 
organelles (filopodia, invadopodia) and inability to promote DQ-collagen IV degradation.  
Together, these observations reveal a previously unrecognized suppressor of invasive 
membrane protrusions and therapeutic target, VASP Ser239 phosphorylation, for 
colorectal cancer. 
MATERIAL AND METHODS 
Reagents.  ST was prepared as described,5 while 8-br-cGMP was obtained from Sigma-
Aldrich (St. Louis, MO).  Antibodies to human VASP, phosphorylated VASP at Ser157, 
GAPDH, villin and cortactin were from Santa Cruz Biotechnology (Santa Cruz, CA).  
Two anti-phoshorylated VASP at Ser239 antibodies were purchased, including clone 
16C2 from Abcam (Cambridge, MA) and a rabbit antibody from Sigma-Aldrich.  The 
anti-human guanylin antibody was from BioDesign International (Saco, ME), while the 
anti-human PKG was obtained from Assay Designs (Ann Arbor, MI).  The antibody to 
the human GCC was obtained from Rockland Immunochemicals (Gilbertsville, PA).  
DQ-collagen IV, Alexa fluor 555 anti-rabbit IgG, Alexa fluor 633 anti-mouse IgG, 
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Oregon Green 488 phalloidin and Slowfade Gold with DAPI were obtained from 
Invitrogen (Carlsbad, CA).  Matrigel was from BD Bioscience (Bedford, MA), the 
general matrix metalloproteinase (MMP) inhibitor GM1006 from Calbiochem (San 
Diego, CA), and all the reagents for cell culture from Mediatech Inc. (Herndon, VA). 
Clinical specimens and immunohistochemistry.  Paraffin-embedded specimens from 7 
patients (Supporting Information Table 1) with histologically-confirmed 
adenocarcinomas of the colo-rectum were obtained from the Department of Pathology, 
Anatomy and Cell Biology of Thomas Jefferson University (Philadelphia, PA) under a 
protocol approved by the Institutional Review Board and subjected to 
immunohistochemistry (IHC).  Briefly, following deparaffinization and rehydratation 
(with xylene/ethanol/water washes), antigens in tissue sections (5 μm) were unmasked by 
two consecutive heating cycles (100°C for 5 min in 10 mM citric buffer, pH 6.0).  Then, 
specimens were incubated overnight (4°C) with antibodies (1:100 dilution, unless 
otherwise indicated) against either human guanylin, GCC, PKG, VASP, and 
phosphorylated VASP at Ser157 or Ser239 followed by incubation with the respective 
secondary antibody and DAB substrate (Avidin-biotin kit; Vector Laboratory, 
Burlingame, CA).  Staining intensity was quantified by a blinded pathologist on a 1 to 3 
scale (1, low or absent; 2, medium; 3 high). 
Cell culture.  All the human colon carcinoma cell lines investigated were purchased from 
the American Type Culture Collection (ATCC, Manassas, VA) and used within 6 months 
from resuscitation.  Methods of cell authentication by ATCC include analyses of 
morphological and growth characteristics, isoenzymology and DNA profiles.  T84 and 
HCT-116 human colon carcinoma cells were cultured (37°C, 5% CO2) with 10% fetal 
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bovine serum in DMEM/F12 or DMEM, respectively.  Cells (2-20 passages) were fed 
with fresh medium every third day and split when sub-confluent. 
Plasmids and cell transductions.  Full length VASP cDNA (Invitrogen, Carlsbad, CA) 
was sub-cloned into the Xho1-EcoR1 multiple cloning site of mouse stem cell virus 
(MSCV)-puro retroviral vector.  Point mutations of VASP serines 157 (tcc → gcc) and 
239 (agc → gcc) were performed employing the QuikChange XL Site-Directed 
Mutagenesis kit (Stratagene, La Jolla, CA) to generate VASP mutants with alanine 
substitutions at Ser157 (S157A), Ser239 (S239A) or both (AA).  Green fluorescent 
protein (GFP)-VASP constructs were generated by sub-cloning wild type VASP or the 
VASP mutant S239A in-frame to the C-terminus of GFP using the pRetroQ-AcGFP-Cl 
vector (Stratagene).  HEK 293T17 cells (from ATCC) were transfected with 1 µg of each 
purified MSCV construct plus 1 µg of the packaging vector pCl-Ampho employing 
Fugene transfection reagent (Roche, Basel, Switzerland).  T84 cells were transduced (for 
72 h) with viral supernatants supplemented with 4 µg/ml polybrene, then selected and 
maintained in 5 µg/ml puromycin.  In this way, the following T84 clones stably-
expressing the MSCV-driven gene were generated: VASP, VASP-S157A, VASP-S239A, 
VASP-AA, GFP, GFP-VASP and GFP-VASP-S239A. 
Immunoblot analysis.  Protein samples (40 g in SDS loading buffer) were separated by 
electrophoresis on 10% acrylamide Tris-Glycine gels, transferred to nitrocellulose 
membranes, and probed (1:1,000 each) with rabbit polyclonal antibodies against VASP, 
phosphorylated VASP at Ser157, GAPDH, villin or mouse monoclonal antibody against 
phosphorylated VASP at Ser239 in TBS-Tween (5% milk) overnight at 4°C.  After 
washing the primary antibody, membranes were probed with the appropriate secondary 
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antibody (1:2,000) (SantaCruz Biotechnology) for 1 h at room temperature.  
Immunostained bands were imaged with a Kodak Image Station 4000R and quantified by 
densitometry. 
Immunofluorescence and imaging.  Filopodia dynamics were studied in cancer cells 
cultured on Lab-Tek glass microscope-chambered slides and treated for 2 h with PBS 
(control), the GCC ligand ST (1 μM) or the cGMP analog 8-br-cGMP (5 mM).  
Invadopodia were examined employing glass coverslips coated with 25 l Matrigel and 
incubated at 37°C (10 min) to solidify.  Here, cancer cells were plated drop-wise directly 
onto Matrigel, allowed to firmly adhere (1 h) and equilibrate (24 h) in their culturing 
medium, and finally treated (2 h) with PBS or ST (1 μM).  Following treatments, cells 
were fixed (15 min) with ice-cold paraformaldehyde (4%, in PBS) and permeabilized (10 
min) with 0.1% Triton X-100.  Following overnight incubations (4°C; in PBS containing 
2% bovine serum albumin) with mouse anti-cortactin and/or rabbit anti-VASP antibodies 
(1:100 each) and 5 units/ml Oregon Green 488 phalloidin, cells were incubated (60 min 
at room temperature) with Alexa fluor 633 anti-mouse IgG and/or Alexa fluor 555 anti-
rabbit IgG.  Specificity of antigen/antibody reactions was assessed employing the 
secondary antibody alone.  Some preparations were counterstained with Slowfade Gold 
anti-fade reagent with DAPI to identify cell nuclei.  Images (63x) were acquired with a 
confocal laser scanning microscope (LSM 510, Carl Zeiss, Jena, Germany) equipped with 
a monochrome CCD camera and pseudo-colored with image-analysis software. 
For filopodia measurements, cells were analyzed by differential interference contrast 
(DIC) microscopy.  Filopodial protrusions (≥5 M) were examined on 8-10 random cell 
colonies per treatment (~50-100 filopodia/treatment) by quantifying the number (per cell 
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colony perimeter) and length (the average distance from the cell base to the tip) of 
filopodia.  The cancer cell colony perimeter (~264 ± 41 M) was determined to ensure 
that results from colonies with different sizes could be directly compared.  Measurements 
were performed using the Zeiss LSM Image Browser software (Carl Zeiss Microimaging, 
Thornwood, NY).  For invadopodia analyses, the number and length of individual 
invadopodia (the baso-lateral actin-based membrane projections) per cancer cell were 
quantified (with the Zeiss LSM Image Browser software) on 8-10 random cells per 
treatment from 3-dimensional (3-D) reconstructions created from orthogonal X, Y and Z 
sections of complete Z-stack cell images (at 1 μm increments) of the confocal 
microscope.  Finally, live cell microscopy was performed on culture dishes (fitted on a 
heated stage) of GFP-VASP (n=6) or GFP-VASP-S239A (n=7) cells by acquiring time-
lapse images at 0, 1, 5, 10 and 15 min after treatment with the confocal microscope.  
Analysis of filopodia was performed with Image J (NIH, Bethesda, MD).  The GFP-
based fluorescent signal was quantified at filopodia tips (the distal ¼ of each filopodia), 
along the entire length of each filopodium and throughout the cell body, and normalized 
to the background fluorescence. 
DQ-collagen IV degradation.  Glass coverslips were coated with 20 μl Matrigel 
containing 25 μg/ml DQ-collagen IV and incubated at 37°C (10 min) to solidify.  Cancer 
cells were plated drop-wise directly onto these Matrigel scaffolds, allowed to firmly 
adhere (1 h), and treated (24 h) in their culturing medium with PBS or ST (1 μM).  Then, 
cells were fixed in methanol (-20°C for 15 min) and processed by confocal microscopy to 
generate Z-stack images, as described for invadopodia analyses above.  DQ-collagen IV 
degradation was quantified in 8-10 cells per treatment with the NIH Image J as the mean 
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fluorescent intensity of the fluorescent cleavage product (from DQ-collagen IV) over the 
cell and pericellular area per cell area.  Results were normalized to the background 
fluorescence. 
Statistical analysis.  Unless otherwise indicated, data are mean ± SEM of ≥3 
independent experiments.  Statistical analyses were performed with the Student’s t test. 
RESULTS 
VASP is an intracellular effector of the GCC pathway in colon cancer cells.  VASP is 
expressed in colon cancer cells (46-kDa band; Supporting Information Fig. 1a) and 
distributes to dynamic membrane domains, including cell leading edges (Fig. 1a) and 
invadopodia (Fig. 1b), where it colocalizes with cortactin and actin (Fig. 1b, right 
panels).  Invadopodia identity was confirmed by assessing their ability to focally degrade 
DQ-collagen IV (Fig. 1c), a fluorogenic analog of the basement membrane component 
collagen IV.  In addition, VASP is an intracellular target of ligand-dependent GCC 
signaling in human colon cancer cells,8 and the potent GCC agonist ST4 induced rapid 
phosphorylation of VASP at both Ser157 and Ser239 (Supporting Information Fig. 1b).  
ST effects on VASP were mimicked by the membrane-permeant cGMP analog 8-br-
cGMP (Fig. 1d-e and Supporting Information Fig. 2a) and blocked by the selective PKG 
peptide inhibitor DT217 (Fig. 1e and Supporting Information Fig. 2b), confirming that ST 
induces VASP Ser phosphorylation by activating the GCC/cGMP/PKG pathway in 
human colon cancer cells. 
GCC signaling through VASP is dysregulated in colon cancer.  In the human colon, 
the GCC pathway is constitutively activated by the paracrine hormone guanylin, which 
induces cGMP- and PKG-dependent phosphorylation of specific substrates.1, 4  
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Accordingly, normal colonic mucosa from patients exhibited epithelial cells with VASP 
Ser157 and Ser239 phosphorylation in the context of an intact guanylin-VASP signaling 
axis (Fig. 2a, upper panel).  However, following transformation and loss of endogenous 
ligand expression2-3 this GCC pathway becomes dysregulated (Fig. 2a, upper panel).  
While GCC and PKG exhibited mixed trends with no significant changes, expression of 
guanylin and all the VASP species were significantly reduced in colorectal 
adenocarcinomas compared to their respective normal counterparts (Fig. 2a).  Of 
significance, VASP phosphorylation at Ser157 and Ser239 were the most compromised 
signals of the GCC pathway, reflected by their downregulation in all tumors examined 
(Fig. 2a, middle panel) and maximal loss of expression (Fig. 2a, lower panel).  Thus, loss 
of VASP Ser phosphorylation in colon cancer reflects interruption of effective induction 
and transmission of GCC-VASP signaling, beyond the mere changes in VASP expression 
(Supporting Information Fig. 3). 
VASP Ser239 phosphorylation by GCC activation inhibits cancer cell shape 
mediating migration and invasion.  As VASP regulates membrane protrusion 
geometry18 and is present at cell leading edges and invadopodia (Fig. 1a-b), the 
functional consequences of ligand-dependent GCC signaling through VASP Ser 
phosphorylation on the membrane architecture of colon cancer cells were examined.  
GCC signaling through cGMP significantly reduced the number and length of migratory 
(filopodia; Fig. 2b) and invasive (invadopodia; Fig. 2c) actin-based protrusions.  
Filopodia identity was confirmed by specific immunostaining with the filopodia marker 
fascin (data not shown).  Importantly, cGMP inhibitory effects were specifically 
mediated by induction of VASP Ser239 phosphorylation, as demonstrated by employing 
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tumor cells stably expressing distinct VASP phosphomutants (Supporting Information 
Fig. 4a).  Thus, cancer cells with VASP-S239A or VASP-AA, which contain point 
mutations at Ser239 and do not accept phosphorylation at that site (Supporting 
Information Fig. 4b), were resistant to GCC-mediated inhibition of filopodia (Fig. 3) and 
invadopodia (Fig. 4).  In contrast, control cells expressing GFP or overexpressing VASP 
and tumor cells with the phosphomutant VASP-S157A, which harbors a point mutation at 
Ser157 only and does not accept phosphorylation at that site (Supporting Information Fig. 
4b), were sensitive to suppression of filopodia (Fig. 3) and invadopodia (Fig. 4) upon 
ligand-dependent GCC signaling.   
VASP Ser239 phosphorylation suppresses invasive membrane protrusions by 
inducing intracellular VASP redistribution.  The molecular mechanism mediating 
inhibition of invasive cell shape by VASP Ser239 phosphorylation was investigated with 
live imaging microscopy in cells stably expressing GFP-VASP constructs (Fig. 5).  Colon 
cancer cells with GFP-VASP, but not mutant cells expressing GFP-VASP-S239A, 
exhibited disassembly of filopodia (Fig. 5a) and invadopodia (Fig. 5b) upon ligand-
dependent GCC activation.  Protrusion retraction by GCC (Fig. 5c) reflected rapid 
removal of VASP from membrane projections (Fig. 5d), with a calculated half-life of 
8.11 min (Supporting Information Fig. 5), and VASP redistribution to inner cell 
compartments away from membrane tips (Fig. 5e).  However, the GFP-VASP-S239A 
mutant (resistant to Ser239 phosphorylation), was insensitive to GCC signaling (Fig. 5c), 
and retained its localization (Fig. 5d) and distribution (Fig. 5e) at locomotory membrane 
extensions, suggesting that VASP Ser239 phosphorylation represents a disassembly 
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signal for invasive migratory organelles by uncoupling VASP from actin-based 
microregions at colon cancer cell membranes. 
VASP Ser239 phosphorylation prevents DQ-collagen IV degradation by colon 
cancer cells.  Metastatic cancer dissemination requires degradation and remodeling of the 
surrounding environment,19 a malignant attribute conferred to colon cancer cells by their 
invadopodia (Fig. 1c).  Strikingly, activation of GCC signaling through VASP abolished 
the cancer ability to degrade DQ-collagen IV, with similar magnitude to that of a general 
inhibitor of MMPs (Fig. 6a), enzymes mediating tumor matrix degradation.20  However, 
colon cancer cells with VASP-S239A or VASP-AA, but not VASP-S157A, did continue 
to proteolytically digest DQ-collagen IV following ligand-dependent GCC signaling (Fig. 
6a), indicating that VASP Ser239 phosphorylation mediates arrest of invadopodia-
mediated proteolysis by the GCC pathway.  Thus, VASP Ser239 phosphorylation is a 
unique biochemical reaction that suppresses membrane protrusions promoting tumor 
invasion in colorectal cancer (Fig. 6b). 
DISCUSSION 
The antitumorigenic GCC signalome is deregulated during colorectal transformation 
reflecting loss of endogenous ligand expression.1-3  Present findings reveal that this 
alteration affects a cGMP-dependent intracellular pathway comprising VASP as the distal 
effector, with subsequent silencing of an important biochemical reaction, VASP Ser239 
phosphorylation, which opposes malignant cell shape.  Interruption of GCC-VASP 
signaling, in turn, results in specific depletion of the VASP phosphospecies, which 
represent previously undescribed biomarkers for GCC deregulation and tumorigenesis in 
colon cancer.  Conversely, restoration of GCC signaling by ligand replacement therapy 
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may provide a rationale strategy for reconstituting cGMP-VASP circuitry and preventing 
metastasis.  Indeed, ligand-dependent GCC activation compromises motility and 
metastasis of colon cancer cells,21 presumably by targeting VASP signaling suppressing 
invasive membrane protrusions (Fig. 6b) described herein. 
Membrane protrusion extension principally reflects the balance of antagonistic forces at 
actin filament barbed ends imposing persistence (anti-capping proteins) or arrest (capping 
proteins) of actin polymerization.10  VASP is a critical anti-capping protein that initiates 
and maintains dynamic membrane regions by orchestrating a cytoskeletal assembly-line 
promoting simultaneous F-actin elongation and bundling.10, 22  In this way, Ena/VASP 
family members control migration and membrane protrusion formation underlying 
important physio(patho)logical processes, from wound-healing, platelet aggregation and 
neural development9 to inflammation, cancer spreading and metastasis.9, 23-24  
Accordingly, expression of Ena/VASP proteins positively correlates with disease 
progression in patients with lung25 or breast26 cancer, suggesting their involvement in 
carcinogenesis and metastasis.  The present study underscores the critical role of VASP 
in organizing cancer functions associated with the malignant membrane shape.  In that 
context, although with unclear activities VASP is a molecular component of 
invadopodia,27 cancer cell projections mediating focal matrix proteolysis.  Here, colon 
cancer cells required VASP for invadopodia stability and function, indicating that VASP 
maintains the structural integrity of these invasive protrusions.  Indeed, intracellular 
VASP redistribution and removal from protrusive tips, upon GCC-dependent 
phosphorylation, destabilizes actin-driven membrane extensions (Fig. 5) by presumably 
depleting actin filament plus-ends of VASP-mediated anti-capping forces,22 resulting in 
 15
protrusion retraction from the persistent actin retrograde flow.  Importantly, invadopodia 
represent attractive antimetastatic targets since they function as critical hubs of invasive 
cell behavior, spatially and temporally organizing the activities of actin nucleators and 
regulators (Arp2/3, N-WASP, cortactin), signaling enzymes (Src, Erk1/Erk2, FAK), 
adhesive receptors (integrins β1/β3, CD44), and proteases (MT1-MMP, MMP2, 
MMP9).27-28  Thus, the ability of cGMP-dependent VASP phosphorylation to dismantle 
invadopodia in colon cancer cells (Fig. 4) offers an innovative antiinvadopodial strategy 
to be exploited against tumor metastasis in patients. 
Tumor suppressors inhibiting metastatic cell dissemination are scarce.  Their critical 
value resides in the potential to serve as biomarkers to improve clinical staging and 
targets to reduce cancer mortality.  VASP Ser239 phosphorylation, a simple intracellular 
biochemical reaction, could represent a unique invasion suppressor with sophisticated 
regulatory dynamics, an inducible mechanism embedded into signal transduction 
networks shaping tumor cell metastasis.  Further, inhibition of metastasis by VASP 
Ser239 phosphorylation could be a general strategy, as VASP is ubiquitously expressed 
across human tissues.9  Of significance, cGMP-dependent VASP Ser157 phosphorylation 
does not appear to affect the invasive phenotype of colon cancer cells (Figs. 3, 4 and 6).  
Since VASP Ser239 is selectively regulated by PKG-dependent phosphorylation,9, 14 
while VASP Ser157 is a more promiscuous site phosphorylated by PKG, cAMP-
dependent protein kinase, and protein kinase C-dependent and -independent 
mechanisms,11, 29 present observations suggest a unique role of the GCC/cGMP/PKG 
pathway in suppressing colorectal cancer invasion through VASP Ser239.  Reduced 
levels of VASP Ser157 phosphorylation in colon cancer (Fig. 2a), in turn, may reflect 
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more complex deregulation of tumor intracellular networks, including cGMP-dependent 
and -independent pathways, probably affecting carcinogenetic processes beyond GCC-
regulated invasive cell shape, a model currently being explored in this laboratory. 
Present findings also support the existence of a biological divergence between cGMP and 
cAMP signaling on Ena/VASP activities, an established paradigm in neurons where the 
cAMP-VASP axis mediates attractive guidance cues by increasing the number and length 
of filopodia, while the cGMP/PKG/VASP pathway promotes repulsive guidance cues.30-
31  However, the precise consequences of cyclic nucleotide signaling through VASP on 
the actin cytoskeleton appear to be cell and tissue specific, as demonstrated by identical 
cGMP and cAMP inhibitory actions on platelet aggregation, reflecting respective VASP 
phosphorylation mechanisms.32  Regardless, VASP Ser239 phosphorylation induced by 
cGMP is emerging as a pivotal mechanism mediating VASP redistribution and 
disassembly of VASP-regulated membrane protrusions, including filopodia and 
lamellipodia.14, 33-34  In that context, Ser239 is strategically located within the EVH2 
domain of VASP, immediately adjacent to the G-actin binding site, which localizes 
VASP at filopodial tips and coordinates the transfer of profilin-bound G-actin to the 
barbed end of the elongating F-actin filament.33  Phosphorylation of VASP Ser239 
interferes with EVH2-dependent processes at membrane leading edges, destabilizing 
VASP-actin interactions and organelle protrusive dynamics.14, 33  Moreover, VASP 
Ser239, but not VASP Ser157, phosphorylation inhibits VASP-driven F-actin 
polymerization.13  This study demonstrates VASP Ser239 phosphorylation suppresses the 
invasive actin cytoskeleton of tumor cells and represents an unappreciated prototype to be 
exploited in innovative diagnostic and therapeutic approaches for colorectal cancer.  
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Specifically, ligand-dependent GCC signaling may prevent colon cancer metastasis by 
neutralizing oncogenic VASP functions at the invasive cancer front. 
 18
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FIGURE LEGENDS 
Fig. 1.  VASP Ser phosphorylation is induced by GCC activation in colon cancer cells.  
(a) Cell leading edges (multi-arrows in upper-left panel) of T84 human colon carcinoma 
cells (on 2-D surfaces) were imaged (magnification, 63x) by DIC and confocal 
microscopy following immunofluorescent staining with phalloidin (green) and anti-
VASP antibody (red).  Yellow in merged image indicates F-actin and VASP 
colocalization at leading tips.  (b) Representative confocal microscopy images of 
invadopodia from T84 cells grown on 3-D Matrigel scaffolds (Matrigel/air interfaces, 
dotted lines in top panels).  Boxes in cartoons on left indicate visual planes in vertical 
(top panels) and horizontal (middle panels) cross-sections from Z-stack images.  Cells 
were immunofluorescently stained for invadopodial marker cortactin (ref. 27) (blue), 
VASP (red) and F-actin (green).  In merged images, white (upper panels) and 
coincidence of picks (bottom panels) from distinct fluorescent signals along lines 
depicted in middle panels indicate cortactin, VASP and F-actin colocalization.  (c) 
Vertical or horizontal (bottom-right) T84 cell cross-sections of confocal microscopy 
images obtained as in b.  Here, Matrigel contained DQ-collagen IV, which releases a 
fluorescent product (green) upon cleavage by extracellular proteases.  Application of 60 
nM of the broad MMP inhibitor GM6001 (iMMP) was employed to prevent DQ-collagen 
IV degradation by tumor cells (ref. 20) and serve as the negative control condition.  Red 
in right panels reflects F-actin staining.  (d) Immunoblots of a representative experiment 
with T84 cells, treated with the GCC ligand ST (1 μM, 5 min) or the cGMP analog 8-br-
cGMP (5 mM, 30 min).  pS157-VASP and pS239-VASP, VASP phosphorylated at 
Ser157 and Ser239, respectively; GAPDH, the loading control.  (e) Bar graphs reflect 
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densitometric quantification of immunobands, normalized to respective loading 
(GAPDH) and vehicle (PBS) controls (CTR), from experiments with T84 and HCT116 
colon cancer cells treated as in d.  Some conditions also received the peptide DT2 (5 μM, 
30 min) to selectively and completely inhibit PKG-Iα activity (Ki, 12.5 nM; ref. 17).  *, P 
< 0.05, versus respective PBS control. 
Fig. 2.  GCC signaling through VASP is disrupted in colon cancer and its reconstitution 
in vitro suppresses dynamic membrane regions.  (a, upper panel) Representative IHC 
images (magnification, 20x) of primary tumor (Tumor) and matched normal adjacent 
tissue (NAT) from 7 patients with colorectal cancer.  Tissues were stained with the 
specific primary antibody (brown) and hematoxylin (blue, nuclei).  The primary antibody 
for VASP phosphorylated at Ser239 was clone 16C2 from Abcam.  (a, middle panel) 
Distribution (percentages indicated in boxes) of patients with different expression levels 
(by staining intensity, as per Material and Methods) of the GCC pathway components.  
The fraction of patients with upregulation (↑) or downregulation (↓) of the indicated 
protein in tumors compared to respective NATs is provided in bottom.  (a, lower panel) 
Differential protein expression (the delta of staining intensity scores) in colorectal tumors 
compared to matched NATs.  *, P < 0.05; ***, P < 0.005 of tumors versus NATs.  
pS157-VASP and pS239-VASP, VASP phosphorylated at Ser157 and Ser239, 
respectively.  (b) Filopodia (arrows in upper-left slide) were imaged in cancer cell 
colonies by DIC.  (c) Invadopodia were imaged by confocal microscopy in single T84 
cells, immunofluorescently stained with 4',6-diamidino-2-phenylindole (DAPI, for nuclei 
in blue) and phalloidin (for F-actin in green).  Boxes in cartoons on top indicate visual 
planes in vertical (left panels) and horizontal (right panels) cross-sections from Z-stack 
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images.  In b-c, number and length of filopodia and invadopodia were quantified as 
described in Material and Methods, and results are shown in bar graphs.  Treatments (2 h) 
were PBS (the vehicle control), ST (1 μM), or 8-bromo-cGMP (5 mM).  *, P < 0.05, 
versus respective PBS control. 
Fig. 3.  VASP Ser239 phosphorylation by GCC disrupts colon cancer cell filopodia.  T84 
cells were treated (with the PBS control or 1 μM ST to induce GCC signaling), imaged 
and analyzed for quantification of filopodia as in Fig. 2b.  Cancer cells stably expressed 
the indicated MSCV-driven genes (see Material and Methods for details), including the 
controls GFP and VASP, and VASP-S157A (S157A), VASP-S239A (S239A) and 
VASP-AA (AA).  Arrows in upper panels indicate representative filopodia.  Bars, 10 µm.  
*, P < 0.05 versus respective control. 
Fig. 4.  VASP Ser239 phosphorylation by GCC disrupts colon cancer cell invadopodia.  
T84 cells were treated (with the PBS control or 1 μM ST to induce GCC signaling), 
imaged and analyzed for quantification of invadopodia as in Fig. 2c.  Cancer cells stably 
expressed the indicated MSCV-driven genes (see Material and Methods for details), 
including the control VASP, and VASP-S157A (S157A), VASP-S239A (S239A) and 
VASP-AA (AA).  Boxes in cartoons on left of top images indicate visual planes in 
vertical (upper panels) and horizontal (bottom panels) cross-sections from Z-stacks.  *, P 
< 0.05 versus respective control. 
Fig. 5.  VASP Ser239 phosphorylation induces membrane protrusion retraction in colon 
cancer cells.  Fluorescently-tagged VASP constructs, GFP-VASP (VASP) and GFP-
VASP-S239A (S239A), were stably expressed in T84 cells as described in Material and 
Methods.  GCC signaling was induced with ST (1 μM), while PBS was the vehicle 
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control.  (a) Representative time course of a live cell experiment analyzing filopodial 
kinetics by confocal microscopy, performed as detailed in Material and Methods.  
Photographs reflect merged DIC and confocal microscopy images.  (b) Representative 3-
D projections from live imaging (confocal microscopy) analyzing invadopodia in single 
tumor cells plated on Matrigel scaffolds.  Cartoons on top indicate visual vertical (left 
panels) and basolateral en face (right panels) perspectives of 3-D reconstructions from Z-
stack images.  (c) The length of filopodia following treatments for 15 min was quantified 
as in Fig. 2b and expressed as percentages of respective PBS controls.  (d) Quantification 
of GFP-tagged VASP signals at filopodia tips from experiments shown in a.  Results are 
percentages of respective time 0 (before ST administration) controls.  (e) Quantification 
of GFP-tagged VASP signals in cell bodies (CB) and filopodia (F) before (CTR, time 0 
control) and after ST (15 min) treatments, as shown in a.  AU, arbitrary units.  *, P < 0.05 
versus respective control. 
Fig. 6.  VASP Ser239 phosphorylation inhibits the cleavage of DQ-collagen IV by colon 
cancer cells.  (a) T84 cells stably-expressing the indicated MSCV-driven genes (VASP, 
the control; VASP-S157A, S157A; VASP-S239A, S239A; VASP-AA, AA) were treated 
for 24 h with PBS, 1 μM ST or 60 nM of the broad MMP inhibitor GM6001 (iMMP), 
imaged and analyzed by confocal microscopy for quantification of DQ-collagen IV 
degradation as detailed in Material and Methods.  Photographs (top) are merged DIC and 
confocal microscopy images.  Results (bottom) are expressed as arbitrary units (AU) of 
the fluorescent signal from the cleaved collagen product.  WT, wild-type T84 cells.  *, P 
< 0.05, versus respective PBS control.  (b) Proposed role of VASP in colorectal 
carcinogenesis.  During tumor progression, VASP phosphorylation at Ser239 (p-Ser239-
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VASP) is reduced, reflecting a dysregulated GCC pathway with interruption of cGMP-
mediated signaling, which promotes the formation of migratory membrane protrusions 
and cancer cell invasion.  Reconstitution of GCC and cGMP signaling, in turn, provides a 
unique therapeutic opportunity to restrain the invasive tumor cell shape and prevent 
metastasis. 
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